Hydromer, Inc. (OTC: HYDI), a leader in medical device coating technologies, has announced its preliminary unaudited financial results for the third quarter of 2024, revealing a 67% increase in net income despite a 21% revenue decline. The company reported revenue of $788,000, down from $993,000 in the same quarter of 2023, attributing the decrease to past raw material management issues and reduced orders from legacy programs.
Despite the revenue setback, Hydromer's strategic cost management led to a 28% reduction in the cost of goods sold to $134,000 and a 24% decrease in operating expenses to $583,000. These efforts culminated in a net income of $72,000, up from $43,000 in the previous year, underscoring the company's ability to navigate market challenges effectively.
As an ISO 9001:2015 certified company, Hydromer continues to serve a global clientele, maintaining compliance with FDA, GMP, ISO 13485, and ISO 9001 standards. Its diverse portfolio of patented coating technologies positions it as a competitive player in the surface modification sector, catering to various industries beyond medical applications.
The preliminary financial results highlight Hydromer's resilience and adaptability, with the significant net income increase suggesting effective operational strategies. The medical device coating industry's demand for advanced technologies presents opportunities for Hydromer to leverage its improved cost structure for future growth.
Stakeholders are optimistic about Hydromer's potential for recovery and growth, as the company's ability to maintain profitability during revenue challenges indicates underlying strength. The focus on innovation and operational efficiency may well position Hydromer for success in the evolving global market.
